PALI - הכנסה תפעולית לפני ניכוי פחת Palisade Bio Inc.

Risks of Phase 2 trial failures and capital shortages are driving volatility, which the GURU.Markets platform reflects through cash-equivalent operating profit, where the parameter value equals 0.00. However, the gastrointestinal recovery business is non-cyclical and independent of macroeconomic trends. A stable staff of researchers and the targeted hiring of pharmacologists currently support the resilience of Palisade Bio, Inc. (PALI).

Palisade Bio, Inc. (PALI) faces a critical dependence on a single drug and a constant need for additional equity financing, making operational efficiency a key factor for survival. An analysis of EBITDA allows for an assessment of the real cash flow from core operations, excluding depreciation and debt load, which characterizes this security as a high-risk speculative asset.